#Switzerland #NLS Pharmaceutics #Zurich #CNS Therapy #Aexon Labs

NLS Pharmaceutics Expands CNS Pipeline with AEX-6xx Series

NLS Pharmaceutics Ltd., a clinical-stage biopharmaceutical company based in Switzerland, has recently announced a significant advancement in its research and development efforts. The company has confirmed the expansion of its DOXA platform with a new class of small molecules known as the AEX-6xx series. This initiative, executed in collaboration with Aexon Labs, focuses on addressing critical issues related to cognition, arousal stability, and neuroprotection, specifically targeting various central nervous system (CNS) disorders.

Unique Therapeutic Approach

The AEX-635 compound, a pivotal element of the AEX-6xx series, provides a unique dual-action mechanism by modulating Multidrug Resistance-Associated Protein 1 (MRP1). This innovative approach is designed to enhance neuroprotective effects, particularly in oxidative stress-related conditions such as Parkinson's disease and gliopathies. Dr. Eric Konofal, the founder and Chief Scientific Officer of Aexon Labs, expressed optimism regarding the robust preclinical data that supports this new initiative, stating, "The AEX-6xx program significantly extends the translational scope of the DOXA platform."

This program not only incorporates cutting-edge small molecules but also includes a novel class of dihydroquinazoline and dihydrobenzothiazine derivatives. These compounds function by integrating dual orexin receptor agonism with cathepsin H inhibition, which are essential for maintaining sleep-wake balance and neuronal resilience.

Expanding Research and Development

In expanding their CNS pipeline, NLS Pharmaceutics aims to capitalize on the promising preclinical findings. The lead indications for development include Type 1 Narcolepsy (NT1), Idiopathic Hypersomnia, ADHD, and various neurodegenerative diseases such as synucleinopathies and Huntington's disease. The initial preclinical results show promising outcomes, with reductions in symptoms like cataplexy and increases in wakefulness in animal models affected by narcolepsy.

Financial Strength and Strategic Outlook

To support these developments, NLS Pharmaceutics has bolstered its financial position with recent fundraising efforts, securing approximately $7 million in equity financing and a $25 million equity line of credit. This funding stream is intended to sustain operations over the next year, creating a strong base for the advancement of clinical programs. NLS Pharmaceutics, alongside Aexon Labs, is on track to leverage these resources strategically for upcoming investigational studies.

CEO Alexander Zwyer highlighted the alignment of the AEX-6xx series with the broader mission of NewCelX, the new entity formed after the merger between NLS and Kadimastem Ltd. This merger aims to combine neuroscience and cell therapy innovations, creating pioneering solutions for complex neurological and metabolic disorders. He stated, "This platform expansion positions NLS and Aexon Labs at the forefront of multi-target CNS innovation."

Future Directions

Looking ahead, the company plans to engage in preclinical partnering discussions and initiate co-development efforts by Q4 2025. The unified branding under NewCelX Ltd. will feature a new website and social media presence that emphasize the innovative strides being taken in CNS therapies. With the integration of advanced drug discovery techniques, NLS Pharmaceutics and Aexon Labs are committed to making strides in treating significant CNS challenges.

NLS Pharmaceutics remains focused on refining its product offerings and ensuring that the latest advancements are both scientifically robust and clinically relevant. The AEX-6xx series represents a significant step toward pioneering therapies that address critical needs in the field of CNS disorders, showcasing NLS Pharmaceutics' commitment to innovation and excellence.